DE69505657T2 - Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren - Google Patents

Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren

Info

Publication number
DE69505657T2
DE69505657T2 DE69505657T DE69505657T DE69505657T2 DE 69505657 T2 DE69505657 T2 DE 69505657T2 DE 69505657 T DE69505657 T DE 69505657T DE 69505657 T DE69505657 T DE 69505657T DE 69505657 T2 DE69505657 T2 DE 69505657T2
Authority
DE
Germany
Prior art keywords
fluorcarbonetherhybrids
methods
physiologically acceptable
acceptable emulsions
containing physiologically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69505657T
Other languages
English (en)
Other versions
DE69505657D1 (de
Inventor
George Moore
Richard Flynn
Miguel Guerra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/246,962 external-priority patent/US5476974A/en
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Publication of DE69505657D1 publication Critical patent/DE69505657D1/de
Application granted granted Critical
Publication of DE69505657T2 publication Critical patent/DE69505657T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
    • A62D1/00—Fire-extinguishing compositions; Use of chemical substances in extinguishing fires
    • A62D1/0028—Liquid extinguishing substances
    • A62D1/0035—Aqueous solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D12/00—Displacing liquid, e.g. from wet solids or from dispersions of liquids or from solids in liquids, by means of another liquid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B23—MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
    • B23K—SOLDERING OR UNSOLDERING; WELDING; CLADDING OR PLATING BY SOLDERING OR WELDING; CUTTING BY APPLYING HEAT LOCALLY, e.g. FLAME CUTTING; WORKING BY LASER BEAM
    • B23K35/00—Rods, electrodes, materials, or media, for use in soldering, welding, or cutting
    • B23K35/22—Rods, electrodes, materials, or media, for use in soldering, welding, or cutting characterised by the composition or nature of the material
    • B23K35/38—Selection of media, e.g. special atmospheres for surrounding the working area
    • B23K35/386—Selection of media, e.g. special atmospheres for surrounding the working area for condensation soldering
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/24—Preparation of ethers by reactions not forming ether-oxygen bonds by elimination of halogens, e.g. elimination of HCl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/48—Preparation of compounds having groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/04—Saturated ethers
    • C07C43/12—Saturated ethers containing halogen
    • C07C43/123—Saturated ethers containing halogen both carbon chains are substituted by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/04—Saturated ethers
    • C07C43/12—Saturated ethers containing halogen
    • C07C43/126—Saturated ethers containing halogen having more than one ether bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/192—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/30—Compounds having groups
    • C07C43/313—Compounds having groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C07C59/135—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2203/00—Foams characterized by the expanding agent
    • C08J2203/14—Saturated hydrocarbons, e.g. butane; Unspecified hydrocarbons
    • C08J2203/146—Saturated hydrocarbons containing oxygen and halogen atoms, e.g. F3C-O-CH2-CH3
DE69505657T 1994-05-20 1995-05-19 Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren Expired - Fee Related DE69505657T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/246,962 US5476974A (en) 1994-05-20 1994-05-20 Omega-hydrofluoroalkyl ethers, precursor carboxylic acids and derivatives thereof, and their preparation and application
US08/437,299 US5502094A (en) 1994-05-20 1995-05-17 Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
PCT/US1995/006327 WO1995031965A1 (en) 1994-05-20 1995-05-19 Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods of use

Publications (2)

Publication Number Publication Date
DE69505657D1 DE69505657D1 (de) 1998-12-03
DE69505657T2 true DE69505657T2 (de) 1999-07-15

Family

ID=26938352

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69505657T Expired - Fee Related DE69505657T2 (de) 1994-05-20 1995-05-19 Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren

Country Status (8)

Country Link
US (2) US5502094A (de)
EP (1) EP0759742B1 (de)
JP (1) JPH10500689A (de)
AU (1) AU2596695A (de)
CA (1) CA2188872C (de)
DE (1) DE69505657T2 (de)
RU (1) RU2159610C2 (de)
WO (1) WO1995031965A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795915C1 (ru) * 2022-07-12 2023-05-15 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) 1,2-БИС(ПЕРФТОР-трет-БУТОКСИ)ЭТАН В КАЧЕСТВЕ КОНТРАСТНОГО ВЕЩЕСТВА ДЛЯ МАГНИТНО-РЕЗОНАНСНОЙ ТОМОГРАФИИ НА ЯДРАХ 19F

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US20020150539A1 (en) * 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5628930A (en) * 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5736121A (en) 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
IT1283203B1 (it) * 1996-03-07 1998-04-16 Ausimont Spa Composizioni estinguenti la fiamma
EP0935415B1 (de) 1996-05-01 2006-11-22 Imarx Pharmaceutical Corp. In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
ATE366588T1 (de) 1996-09-11 2007-08-15 Imarx Pharmaceutical Corp Verfahren zur diagnostischen bilderzeugung der nierenregion unter verwendung eines kontrastmittels und eines vasodilators
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
AU4915197A (en) * 1996-10-17 1998-05-11 Advanced Chemical Design, Inc. Environmentally safe bromopentane composition for cleaning metallic, electrical and plastic materials
US6331286B1 (en) 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
EP1001816A4 (de) * 1996-11-25 2002-07-17 Imarx Pharmaceutical Corp Perfluoriete ethern zusammensetzungen wie kontrastmittel
US6020298A (en) * 1997-03-05 2000-02-01 Ausimont S.P.A. Solvent cleaning agents including additives of the formula Rf -CFX-L containing perfluoroalkylenic units
US6537246B1 (en) * 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6221261B1 (en) 1997-08-13 2001-04-24 Edward E. Boss Process for treating sewage using hydro fluoro ether polymers
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US8974363B2 (en) 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US6070465A (en) * 1998-08-24 2000-06-06 Dresser Industries Free water measurement apparatus and method thereof
US20040047804A1 (en) * 1998-10-29 2004-03-11 The General Hospital Corporation, A Massachusetts Corporation Enhanced radiation therapy
US6308714B1 (en) 1998-11-10 2001-10-30 Coraje, Inc. Ultrasound enhanced chemotherapy
US6159917A (en) * 1998-12-16 2000-12-12 3M Innovative Properties Company Dry cleaning compositions containing hydrofluoroether
US6127430A (en) * 1998-12-16 2000-10-03 3M Innovative Properties Company Microemulsions containing water and hydrofluroethers
US8470296B2 (en) * 1998-12-21 2013-06-25 Provectus Pharmatech, Inc. Intracorporeal medicaments for high energy phototherapeutic treatment of disease
US20020001567A1 (en) * 1998-12-21 2002-01-03 Photogen, Inc. Intracorporeal medicaments for high energy phototherapeutic treatment of disease
US7384623B1 (en) 1998-12-21 2008-06-10 Provectus Pharmatech, Inc. High energy phototherapeutic agents
WO2003059162A1 (en) * 2002-01-15 2003-07-24 Broad Of Regents, The University Of Texas System Methods and compositions to reduce scattering of light during therapeutic and diagnostic imaging procedures
ES2305368T3 (es) * 2002-05-10 2008-11-01 THE PROCTER & GAMBLE COMPANY Tisu estampado en relieve que tiene fibras superficiales sueltas y metodo para su produccion.
US20090117207A1 (en) * 2005-11-29 2009-05-07 Zoltani Csaba K Methods and compositions for treatment of poison-caused pathology
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
US8575403B2 (en) 2010-05-07 2013-11-05 Celanese International Corporation Hydrolysis of ethyl acetate in ethanol separation process
WO2011130304A2 (en) * 2010-04-12 2011-10-20 University Of South Florida Materials and methods for reliable measurement of blood volume
US9272970B2 (en) 2010-07-09 2016-03-01 Celanese International Corporation Hydrogenolysis of ethyl acetate in alcohol separation processes
US8859827B2 (en) 2011-11-18 2014-10-14 Celanese International Corporation Esterifying acetic acid to produce ester feed for hydrogenolysis
US8710279B2 (en) 2010-07-09 2014-04-29 Celanese International Corporation Hydrogenolysis of ethyl acetate in alcohol separation processes
US8664454B2 (en) 2010-07-09 2014-03-04 Celanese International Corporation Process for production of ethanol using a mixed feed using copper containing catalyst
US8927787B2 (en) 2011-04-26 2015-01-06 Celanese International Corporation Process for controlling a reboiler during alcohol recovery and reduced ester formation
CN103080053B (zh) 2011-04-26 2015-08-12 国际人造丝公司 使用叠置床反应器生产乙醇的方法
US8592635B2 (en) 2011-04-26 2013-11-26 Celanese International Corporation Integrated ethanol production by extracting halides from acetic acid
US9073816B2 (en) 2011-04-26 2015-07-07 Celanese International Corporation Reducing ethyl acetate concentration in recycle streams for ethanol production processes
US8754268B2 (en) 2011-04-26 2014-06-17 Celanese International Corporation Process for removing water from alcohol mixtures
US8895786B2 (en) 2011-08-03 2014-11-25 Celanese International Corporation Processes for increasing alcohol production
US8853468B2 (en) 2011-11-18 2014-10-07 Celanese International Corporation Vapor esterification method to produce ester feed for hydrogenolysis
US8802901B2 (en) 2011-11-18 2014-08-12 Celanese International Corporation Continuous ethyl acetate production and hydrogenolysis thereof
US9024089B2 (en) 2011-11-18 2015-05-05 Celanese International Corporation Esterification process using extractive separation to produce feed for hydrogenolysis
US8829249B2 (en) 2011-11-18 2014-09-09 Celanese International Corporation Integrated esterification and hydrogenolysis process for producing ethanol
US8748673B2 (en) 2011-11-18 2014-06-10 Celanese International Corporation Process of recovery of ethanol from hydrogenolysis process
US8829251B2 (en) 2011-11-18 2014-09-09 Celanese International Corporation Liquid esterification method to produce ester feed for hydrogenolysis
US8927790B2 (en) 2011-12-15 2015-01-06 Celanese International Corporation Multiple vapor feeds for hydrogenation process to produce alcohol
US8975451B2 (en) 2013-03-15 2015-03-10 Celanese International Corporation Single phase ester feed for hydrogenolysis
ES2541226B2 (es) * 2014-01-15 2016-02-12 MONDRAGÓN GOI ESKOLA POLITEKNIKOA J. Mª. ARIZMENDIARRIETA, S.C Fantoma de sangre
US11406722B2 (en) 2017-03-16 2022-08-09 The Board Of Regents Of The University Of Texas System Nanodroplets with improved properties
JP7002205B2 (ja) * 2017-03-23 2022-01-20 株式会社グッドマン シミュレータ用擬似体液及び医療用シミュレータ
US10814268B2 (en) 2018-03-29 2020-10-27 Samuel L. Shepherd Process for separating gases from gas mixtures using hydro fluoro ether

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493581A (en) * 1968-05-09 1970-02-03 Basf Ag Imidazolium salts
US3911138B1 (en) * 1973-02-26 1996-10-29 Childrens Hosp Medical Center Artificial blood and method for supporting oxygen transport in animals
JPS5331209B2 (de) * 1973-10-05 1978-09-01
MX143186A (es) * 1975-11-04 1981-04-01 Silver Seiko Mejoras en maquina tejedora con un lector de programa
JPS5835485B2 (ja) * 1976-02-03 1983-08-03 株式会社ミドリ十字 酸素運搬輸液
US4110474A (en) * 1977-08-26 1978-08-29 Suntech, Inc. Tetramethylpentane blood substitutes
US4187252A (en) * 1977-08-26 1980-02-05 Suntech, Inc. Tetramethylpentane blood substitutes
US4186253A (en) * 1978-10-10 1980-01-29 The Green Cross Corporation Perfusate for preserving organ to be transplanted and preserving method
US4252827A (en) * 1979-05-23 1981-02-24 The Green Cross Corporation Oxygen-transferable fluorocarbon emulsion
US4443480A (en) * 1982-04-12 1984-04-17 Children's Hospital Medical Center Artificial blood and other gas transport agents
US4423077A (en) * 1982-07-27 1983-12-27 The University Of Pennsylvania Perfluorochemical emulsion artificial blood
US4534978A (en) * 1982-12-28 1985-08-13 The Green Cross Corporation Perfluorocycloamines
CA1257828A (en) * 1984-04-16 1989-07-25 William Mccormick Perfluoro compound dispersions containing reduced amounts of surfactant and process of preparation
US4686024A (en) * 1985-02-01 1987-08-11 The Green Cross Corporation Novel perfluoro chemicals and polyfluorinated compounds and process for production of the same
US4868318A (en) * 1985-02-01 1989-09-19 The Green Cross Corporation Perfluoro chemicals and polyfluorinated compounds
US4987154A (en) * 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
DE3785054T2 (de) * 1986-01-24 1993-07-08 Childrens Hosp Medical Center Stabile emulsionen von stark fluorierten, organischen verbindungen.
US4866096A (en) * 1987-03-20 1989-09-12 Air Products And Chemicals, Inc. Stable fluorochemical aqueous emulsions
FR2620445B1 (fr) * 1987-09-16 1990-07-20 Centre Nat Rech Scient Nouveaux derives fluores d'acides amines, utilisables en particulier comme agents tensioactifs ou cotensioactifs et preparations a usage biomedical comprenant ces derives
US5171755A (en) * 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
FR2665705B1 (fr) * 1990-08-09 1993-07-30 Atta Nouveaux derives fluores amphiphiles a structure telomere, leur procede de preparation et leur utilisation dans des preparations a usage biomedical.
FR2679150A1 (fr) * 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795915C1 (ru) * 2022-07-12 2023-05-15 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) 1,2-БИС(ПЕРФТОР-трет-БУТОКСИ)ЭТАН В КАЧЕСТВЕ КОНТРАСТНОГО ВЕЩЕСТВА ДЛЯ МАГНИТНО-РЕЗОНАНСНОЙ ТОМОГРАФИИ НА ЯДРАХ 19F

Also Published As

Publication number Publication date
WO1995031965A1 (en) 1995-11-30
JPH10500689A (ja) 1998-01-20
US5502094A (en) 1996-03-26
CA2188872C (en) 2008-09-16
CA2188872A1 (en) 1995-11-30
DE69505657D1 (de) 1998-12-03
RU2159610C2 (ru) 2000-11-27
EP0759742A1 (de) 1997-03-05
AU2596695A (en) 1995-12-18
US5567765A (en) 1996-10-22
EP0759742B1 (de) 1998-10-28

Similar Documents

Publication Publication Date Title
DE69505657D1 (de) Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
NO972125D0 (no) Hemmoroideblandinger og fremgangsmåte for anvendelse
DE69415157T2 (de) Elektrochirurgischer prozessor und anwendung
DE69611813D1 (de) Trokar und Kanüle
DE59306001D1 (de) Wirbelsäulenimplantat und Repositionsinstrument
DE69607321D1 (de) Reinigungsverfahren und zusammensetzung
DE69609353T2 (de) In der therapie verwendbare chinolin- und chinazolinverbindungen
DE69406116T2 (de) Reinigungszusammensetzung und verwendungsverfahren
DE69228373T2 (de) Kosmetikum und emulsion
DE69719603D1 (de) Kosmetisches Haarwaschmittel und dessen Verwendung
BR9510440A (pt) Estrutura absorvente e produto absorvente descartável
DE69600048T2 (de) Kosmetisches Haarwaschmittel und dessen Verwendung
FR2744442B1 (fr) Preparation du 1,1,1,3,3-pentachlorobutane et du 1,1,1,3,3,-pentafluorobutane
ID18679A (id) Penggunaan terapi lanjutan
NO972477L (no) Meso-mono-jod substituerte tetramakrocykliske forbindelser og fremgangsmåter for fremstilling og anvendelse
DE59710130D1 (de) Verwendung verbindungsverfahrens und verbindungsverfahren
FI965204A (fi) Bromelaiinin lääkekäyttö
DE69732436D1 (de) Sirupe sowie daraus hergestellte eine emulsion enthaltende umhuellungen
BR9505381A (pt) Utilização de ao menos um antagonista de substáncia p e utilização de um antagonista de substáncia p
DE69841550D1 (de) Behandlung von fibromyalgie und verwandten erkrankungen
DE69629027D1 (de) Kosmetische zubereitung zur prävention und beseitigung von hautschäden
FI963263A (fi) Bromelaiinin lääkinnällinen käyttö
NO953003D0 (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
ITRM940124V0 (it) "brandina o cuccia pieghegole e/o smontabile"

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee